NCT03895502 (ONCO DVT) is a Phase 4 clinical trial of 12-month Edoxaban in Venous Thrombosis, sponsored by Takeshi Morimoto.

Who is sponsoring NCT03895502?

NCT03895502 is sponsored by Takeshi Morimoto.

What drugs are being tested in NCT03895502?

Interventions in NCT03895502: 12-month Edoxaban, 3-month Edoxaban.

What condition does NCT03895502 study?

NCT03895502 studies Venous Thrombosis, Neoplasms, Anticoagulant.

Is NCT03895502 still recruiting?

NCT03895502 is currently completed. Last updated 4 October 2023.

Last reviewed 2023-10-04 · How we verify

NCT03895502: ONCO DVT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Optimal Duration of Anticoagulation Therapy for Isolated Distal Deep Vein Thrombosis in Patients With Cancer Study

Completed Phase 4 Last updated 4 October 2023

What this trial tests

Phase 4 trial testing 12-month Edoxaban in Venous Thrombosis in 605 participants. Completed in 31 August 2023.

Timeline

27 May 2019

Primary endpoint
30 June 2023

31 August 2023

Quick facts

Lead sponsor	Takeshi Morimoto
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	605
Start date	27 May 2019
Primary completion	30 June 2023
Estimated completion	31 August 2023
Sites	1 location across Japan

Drugs / interventions tested

12-month Edoxaban — full drug profile →
3-month Edoxaban — full drug profile →

Conditions studied

Venous Thrombosis — all drugs for Venous Thrombosis →
Neoplasms — all drugs for Neoplasms →
Anticoagulant — all drugs for Anticoagulant →

Sponsor

Takeshi Morimoto — full company profile →

Who can join

20 and older, any sex, with Venous Thrombosis or Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine the optimal duration of anticoagulation therapy (3 months versus 12 months) with direct oral anticoagulant (edoxaban) for isolated distal deep vein thrombosis.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Edoxaban for 12 Months Versus 3 Months in Patients With Cancer With Isolated Distal Deep Vein Thrombosis (ONCO DVT Study): An Open-Label, Multicenter, Randomized Clinical Trial.
Yamashita Y, Morimoto T, Muraoka N, Oyakawa T, et al · · 2023 · cited 41× · PMID 37638968 · DOI 10.1161/circulationaha.123.066360
Spontaneous Hemorrhagic Pericardial and Pleural Effusion in a Patient Receiving Apixaban.
Cinelli M, Uddin A, Duka I, Soomro A, et al · · 2019 · cited 13× · PMID 31413784 · DOI 10.14740/cr902
Edoxaban for 12 vs. 3 months in cancer-associated isolated distal deep vein thrombosis according to different doses: insights from the ONCO DVT study.
Chatani R, Yamashita Y, Morimoto T, Muraoka N, et al · · 2024 · cited 5× · PMID 38650055 · DOI 10.1093/ehjcvp/pvae028
Clinical outcomes of cancer-associated isolated distal deep vein thrombosis: a comparison between asymptomatic and symptomatic thrombosis-findings from the ONCO DVT Study.
Ogihara Y, Yamashita Y, Morimoto T, Muraoka N, et al · · 2025 · cited 2× · PMID 40224278 · DOI 10.1016/j.rpth.2025.102722
What's new in the prevention and treatment of cancer-associated thrombosis?
Kimpton M, Carrier M. · · 2019 · cited 2× · PMID 31808858 · DOI 10.1182/hematology.2019000023
Net Clinical Benefit of 12-Month Over 3-Month Edoxaban in Cancer-Associated Isolated Distal Deep Vein Thrombosis.
Nishimoto Y, Yamashita Y, Morimoto T, Muraoka N, et al · · 2024 · cited 1× · PMID 39801633 · DOI 10.1016/j.jaccao.2024.07.019
D-dimer after 3 months of anticoagulation therapy and outcomes in cancer-associated isolated distal deep vein thrombosis.
Nishikawa T, Yamashita Y, Fujita M, Morimoto T, et al · · 2025 · PMID 40766276 · DOI 10.1016/j.bvth.2025.100063
Net Clinical Benefit of Edoxaban for 12 versus 3 Months in Cancer-associated Isolated Distal Deep Vein Thrombosis: ONCO DVT study
Nishimoto Y, Yamashita Y, Morimoto T, Muraoka N, et al · · 2024 · DOI 10.1101/2024.02.27.24303473

Verify or expand the search:

Other recruiting trials for Venous Thrombosis

Currently open trials in the same condition.

NCT06672250 — The Correlation Between Circulatory Tumor Cells and Venous Thrombosis · recruiting
NCT04649489 — A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate · Phase 3 · active not recruiting

Other Takeshi Morimoto trials

Trials by the same sponsor.

NCT04724460 — Optimal Duration of Anticoagulation Therapy for Low-risk Pulmonary Embolism Patients With Cancer · Phase 4 · completed
NCT04691700 — GOREISAN for Heart Failure (GOREISAN-HF) Trial · Phase 4 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03895502 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Takeshi Morimoto
Last refreshed: 4 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03895502.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing